Advertisement
Advertisement
U.S. markets close in 1 hour 36 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Genetron Holdings Limited (GTH)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Visitors trend2W10W9M
0.8100+0.0400 (+5.19%)
As of 01:49PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Performance Outlook
Previous Close0.7700
Open0.7977
Bid0.8000 x 800
Ask0.8200 x 1000
Day's Range0.7501 - 0.8290
52 Week Range0.6930 - 1.2700
Volume130,877
Avg. Volume58,239
Market Cap74.154M
Beta (5Y Monthly)0.53
PE Ratio (TTM)N/A
EPS (TTM)-1.0300
Earnings DateNov 01, 2023 - Nov 02, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.34
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for GTH

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Genetron Holdings Limited
    Analyst Report: I-MabI-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.
    Rating
    Fair Value
    Economic Moat
    last monthMorningstar
View more
  • GlobeNewswire

    Genetron Health Announces Receipt of Notification from Nasdaq

    BEIJING, May 23, 2023 (GLOBE NEWSWIRE) -- Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it has received written notification from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) dated May 17, 2023, indicating that for the

  • GlobeNewswire

    Genetron Health Regains Compliance With Nasdaq Minimum Bid Price Requirement

    BEIJING, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that the Company had received a notification letter (“Compliance Notice”) from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”), dated Jan

  • GlobeNewswire

    Genetron Health Reports Unaudited Second Quarter 2022 Financial Results

    BEIJING, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today reported its unaudited financial results for the second quarter ended June 30, 2022. Recent Business Highlights Received College of American Pathologists (CAP) Accreditation for its laboratory

Advertisement
Advertisement